BioDuro Initiates Effort to Develop COVID-19 Nanobody Therapeutic

BioDuro launches a COVID-19 nanobody therapeutic program, leveraging AI and synthetic antibodies to target viral entry, supported by global health partnerships
March 26, 2020

Sundia and UChem Exhibit in the 20th Korea Organic Synthetic Society Conference

Sundia and UChem presented at the 20th Korea Organic Synthetic Society Conference, highlighting expertise in medicinal chemistry and drug discovery integration
November 21, 2019

BioDuro Launches New Antibody & Cell Therapy Discovery Services

BioDuro launches new antibody and cell therapy discovery services, enhancing biologics development with advanced technologies and validated clinical pathways.
November 20, 2019

BioDuro Welcomes New Chief Financial Officer

Jeffery Blazevich joins BioDuro as CFO, bringing 30+ years of experience in technology, healthcare, and medical devices. His leadership will drive growth and
June 30, 2019

Congratulations to Sinovent for NMPA IND approval

Sinovent achieves NMPA IND approval for XNW7201, an innovative Wnt pathway inhibitor for digestive system tumors, supported by Sundia's comprehensive CRO services.
May 24, 2019
Total 85 12...891011121314...1617
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all